Ironwood Pharmaceuticals, Inc. - (IRWD) News
Filter IRWD News Items
IRWD News Results
|Loading, please wait...|
IRWD News Highlights
- IRWD's 30 day story count now stands at 7.
- Over the past 19 days, the trend for IRWD's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- AGE, AMRX and CD are the most mentioned tickers in articles about IRWD.
Latest IRWD News From Around the Web
Below are the latest news stories about Ironwood Pharmaceuticals Inc that investors may wish to consider to help them evaluate IRWD as an investment opportunity.
These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2021.
Citius Pharmaceuticals (CTXR) acquires Dr. Reddy's exclusive license rights for E7777 to treat a rare form of NHL and other cancer indications.
Takeda's (TAK) pipeline candidate, pevonedistat, fails to achieve statistically significant event-free survival in patients with hematological disorders.
BOSTON, September 02, 2021--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will participate in fireside chats at two upcoming virtual investor conferences in September:
Amneal's (AMRX) IPX-203 increases "Good On" time by 1.55 hours per dose versus immediate-release CD/LD in patients with Parkinson's disease.
BOSTON, August 26, 2021--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that the U.S. Food and Drug Administration (FDA) approved a revised label for LINZESS® (linaclotide) based on clinical safety data that has been generated thus far in pediatric studies. The updated label modifies the boxed warning for risk of serious dehydration and contraindication against use in children to those less than two years of age. The boxed warning and contraindica
Ironwood Pharmaceuticals shares on Thursday rose after it said that the FDA approved a revised label for its Linzess treatment for irritable-bowel syndrome. The revised label warns of the risk of serious dehydration and contraindication against use in children younger than two. Prior to the change, the dehydration warning applied to people younger than 18, and the contraindication applied to those younger than six.
Ironwood (IRWD) witnesses strong demand for Linzess in the second quarter. Stock up.
During today's call, Tom McCourt, our Chief Executive Officer, will provide a brief overview and review our strategic priorities and commercial performance of LINZESS. Jason Rickard, our Chief Operating Officer, will then review our second quarter financial results and provide updated guidance for the year.
BOSTON, August 05, 2021--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported financial results for second quarter 2021 and raised full year 2021 financial guidance.